orphan drug

Drug development is expensive, so companies naturally gravitate to diseases with millions of patients, where the cost can be recouped. Rare diseases, each affecting only a handful of people, were historically left without treatments — the patients were, in effect, orphaned. An orphan drug is a medicine for such a rare condition, and the term carries a specific regulatory meaning tied to deliberate incentives created to fix this market failure.

Governments offer these incentives precisely because the small patient population would otherwise make development uneconomic. Depending on the jurisdiction, a drug granted orphan designation may receive extended market exclusivity, reduced or waived regulatory fees, tax credits for clinical research, and closer guidance from the agency. Eligibility hinges on the disease being rare, defined by a threshold such as fewer than a set number of patients in the population, and often on there being an unmet need.

The policy has genuinely brought treatments to conditions that the market would have ignored, especially many genetic and metabolic disorders. It also has honest tensions: because trials in tiny populations are hard to run and exclusivity can support very high prices, orphan status has occasionally been used in ways that strain the original intent. The core idea remains sound — to make developing a drug for a rare disease worth a company's while.